Announcements Trials
Browse Landscape

Phase

Phase 2 76Phase 3 40Phase 1/2 22Phase 1 19Phase 2/3 4Phase NA 3Phase EARLY_PHASE1 2Phase 4 1

Status

Active not recruiting 2Terminated 1Completed 1

Sponsor Class

NIH 2OTHER 1NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 1Dermatologic 1

Conditions

Lymphoma 6Breast Neoplasms 6Leukemia 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Large B-Cell, Diffuse 4Sarcoma 3Osteosarcoma 3Sarcoma, Synovial 2Sarcoma, Alveolar Soft Part 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Neurofibrosarcoma 2Liposarcoma 2Leukemia, T-Cell 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Fibrosarcoma 2Fallopian Tube Neoplasms 2Chondrosarcoma, Extraskeletal Myxoid 2Triple Negative Breast Neoplasms 1Thymoma 1Thymic epithelial tumor 1The Neoadjuvant Therapy 1Sezary Syndrome 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1Renal Pelvis and Ureter Urothelial Carcinoma 1Perivascular Epithelioid Cell Neoplasms 1Nerve Sheath Neoplasms 1Neoplasms, Connective and Soft Tissue 1

Interventions

Rituximab 8Cyclophosphamide 7Etoposide 5Prednisone 4Doxorubicin 4Vincristine 3Gemcitabine 3Bendamustine Hydrochloride 3prednylidene 2deltacortene 2Specimen Handling 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2CT-P10 2Busulfan 2venetoclax 1umbralisib 1ublituximab 1tebufenozide 1tafasitamab 1selinexor 1huachansu 1fludarabine phosphate 1epratuzumab 1cc-486 1Whole-Body Irradiation 1Vindesine 1VAP-cyclo protocol 1Thiotepa 1Tamoxifen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2/3 × Lymphoma, Large B-Cell, Diffuse × Doxorubicin × Clear all
NCT03984448 2026-05-29

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
363 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
422 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT00060385 2012-09-24

Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2/3 Terminated
3 enrolled
DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00169130 2007-07-13

ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma

Lymphoma Study Association

Phase 2/3 Completed
300 enrolled
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡